Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of low-dose chest CT and multiplex PCR on antibiotic usage for community-acquired pneumonia: multicentre prospective controlled before-after study with cluster randomisation (CAP-NEXT study).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

The role of FDG-PET/CT in assessing cardiac sarcoidosis with no high-risk cardiac features and normal CMR.

European heart journal. Cardiovascular Imaging·2025
Same author

Holter Monitoring and Cardiac Biomarkers in Screening for Cardiac Sarcoidosis.

Lung·2024
Same author

The effect of azithromycin on sputum inflammatory markers in bronchiectasis.

BMC pulmonary medicine·2023
Same author

[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial.

European journal of nuclear medicine and molecular imaging·2023
Same author

The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol.

Contemporary clinical trials communications·2022

Related Experiment Video

Updated: Jun 26, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Rituximab in life threatening antisynthetase syndrome.

E Vandenbroucke1, J C Grutters, J Altenburg

  • 1Department of Pulmonology, University Hospital Ghent, 9000 Ghent, Belgium. elkevandenbroucke@hotmail.com

Rheumatology International
|February 3, 2009
PubMed
Summary

Antisynthetase syndrome, characterized by interstitial lung disease and muscle inflammation, can be severe. This case study shows rituximab effectively treated a patient refractory to other therapies, improving respiratory function.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Experiment Videos

Last Updated: Jun 26, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Area of Science:

  • Rheumatology
  • Pulmonology
  • Immunology

Background:

  • Antisynthetase syndrome is an autoimmune disorder associated with interstitial lung disease (ILD) and muscle inflammation.
  • The presence of anti-Jo-1 and anti-Ro/SSA antibodies can indicate a more severe ILD presentation.
  • This patient presented with life-threatening respiratory failure refractory to standard treatments.

Observation:

  • The patient exhibited severe interstitial pneumonitis, polyarthritis, and polymyositis.
  • Initial treatment with glucocorticoids and cyclophosphamide was ineffective.
  • The patient's condition rapidly improved following two sequential rituximab infusions.

Findings:

  • Rituximab treatment led to rapid clinical improvement in a patient with severe, refractory antisynthetase syndrome.
  • Treatment response correlated with a decrease in serum soluble IL2-receptor levels.
  • Positron emission tomography (PET) scans confirmed reduced pulmonary disease activity post-rituximab.

Implications:

  • Rituximab represents a potential therapeutic option for severe antisynthetase syndrome refractory to conventional treatments.
  • Monitoring soluble IL2-receptor levels may serve as a biomarker for treatment response.
  • PET-scans can effectively assess treatment efficacy in ILD associated with autoimmune conditions.